FindTrial
Sign In

Low-dose decitabine combined with modified busulfan/ cyclophosphamide as a conditioning regimen followed by allogeneic stem cell transplantation for the treatment of high-risk patients with acute myeloid leukaemia: a prospective randomized controlled clinical study

Low-dose decitabine combined with modified busulfan/ cyclophosphamide as a conditioning regimen followed by allogeneic stem cell transplantation for the treatment of high-risk patients with acute myeloid leukaemia: a prospective randomized controlled clinical study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16007755
Enrollment
Unknown
Registered
2016-01-15
Start date
2016-01-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia

Interventions

decitabine group :decitabine combined with modified Bu/Cy conditioning regimen
control group:modified Bu/Cy conditioning regimen

Sponsors

the First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. with inform consent; 2. patients with AML not in remission or in remission (>=CR2), no contraindication for allogeneic transplantation,such as active infection, liver and renal function damage; 3. Aged 12-60 years; 4. suitable donors.

Exclusion criteria

Exclusion criteria: 1. uncontrolled infection or significant bleeding 2. Organ failure 3. with mental disease.

Design outcomes

Primary

MeasureTime frame
Disease-free survival;Overall Survival;—

Secondary

MeasureTime frame
Disease Response;Toxicity;Graft-versus-host disease;Non-relapse mortality;Relapse rate;—

Countries

China

Contacts

Public ContactWu Depei?Tang XiaoWen

the First Affiliated Hospital of Soochow University

xwtang1020@163.com+86 13913538266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026